Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340320 · ClinicalTrials.gov registry record · Phase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Corxel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT07340320 is a Phase 2 study that is actively recruiting participants, run by Corxel Pharmaceuticals. The registered enrollment target is 240 participants.
The verdict
NCT07340320, a Phase 2 study, is actively recruiting participants, sponsored by Corxel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
Interventions
- OTHER Placebo
- DRUG CX11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2027-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07340320
The ClinicalTrials.gov registry entry for NCT07340320 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corxel Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07340320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07340320 about?
NCT07340320 is a clinical study titled "A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus". This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being don...
What is the current status of trial NCT07340320?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-02-06. Estimated completion is 2027-01-07.
What interventions are being tested in trial NCT07340320?
The interventions under investigation include: Placebo (OTHER), CX11 (DRUG).
Who is sponsoring clinical trial NCT07340320?
This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.